title: Oxcarbazepine in a monotherapy trial for partial seizures--placebo-controlled studies in neurology: where do they stop?
authors.forename: S C
authors.initials: SC
authors.lastname: Schachter
authors.forename: B
authors.initials: B
authors.lastname: Vazquez
authors.forename: R S
authors.initials: RS
authors.lastname: Fisher
authors.forename: K D
authors.initials: KD
authors.lastname: Laxer
authors.forename: D
authors.initials: D
authors.lastname: Combs-Cantrell
authors.forename: E
authors.initials: E
authors.lastname: Faught
authors.forename: L J
authors.initials: LJ
authors.lastname: Willmore
authors.forename: G L
authors.initials: GL
authors.lastname: Morris
authors.forename: L
authors.initials: L
authors.lastname: Ojemann
authors.forename: G D
authors.initials: GD
authors.lastname: Montouris
mesh_terms: D000927:Anticonvulsants / Q000627:therapeutic use*; D002220:Carbamazepine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004311:Double-Blind Method; D004569:Electroencephalography / Q000187:drug effects; D004828:Epilepsies, Partial / Q000188:drug therapy*; D004992:Ethics, Medical; D006801:Humans; D000078330:Oxcarbazepine; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D002220:Carbamazepine; D000078330:Oxcarbazepine